Loxo Oncology Announces Acceptance of LOXO-292 Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual M...
April 04 2018 - 6:45AM
Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company
innovating the development of highly selective medicines for
patients with genetically defined cancers, today announced that
interim clinical data from the ongoing Phase 1 clinical trial for
LOXO-292, the company’s highly selective RET inhibitor, will be
presented in an oral presentation at the American Society of
Clinical Oncology (ASCO) Annual Meeting held June 1 - 5, 2018 in
Chicago, Illinois. The presentation is entitled “A Phase 1 Study of
LOXO-292, A Potent and Highly Selective RET Inhibitor, in Patients
with RET-Altered Cancers.”
The Company will be hosting a conference call and webcast to
discuss the data after they are presented at ASCO. Details
regarding the date and time of the presentation and webcast will be
announced closer to the ASCO conference.
About LOXO-292 LOXO-292 is a potent, oral and
selective investigational new drug in clinical development for the
treatment of patients with cancers that harbor abnormalities in the
rearranged during transfection (RET) kinase. RET fusions have been
identified in approximately 2% of non-small cell lung cancer,
10-20% of papillary thyroid cancer, and a subset of colon and other
cancers. RET point mutations account for approximately 60% of
medullary thyroid cancer. Both RET fusion and select RET mutated
cancers are primarily dependent on this single activated kinase for
their proliferation and survival. This dependency, often referred
to as “oncogene addiction,” renders such tumors highly susceptible
to small molecule inhibitors targeting RET. LOXO-292 was designed
to inhibit native RET signaling as well as anticipated acquired
resistance mechanisms that could otherwise limit the activity of
this therapeutic approach. LOXO-292 is currently being studied in
a Phase 1 trial. Interested patients and physicians can
contact the Loxo Oncology Physician and Patient RET Clinical Trial
Hotline at 1-855-RET-4-292 or
email clinicaltrials@loxooncology.com.
About Loxo OncologyLoxo Oncology is a
biopharmaceutical company innovating the development of highly
selective medicines for patients with genetically defined cancers.
Our pipeline focuses on cancers that are uniquely dependent on
single gene abnormalities, such that a single drug has the
potential to treat the cancer with dramatic effect. We believe that
the most selective, purpose-built medicines have the highest
probability of maximally inhibiting the intended target, thereby
delivering best-in-class disease control and safety. Our management
team seeks out experienced industry partners, world-class
scientific advisors and innovative clinical-regulatory approaches
to deliver new cancer therapies to patients as quickly and
efficiently as possible. For more information, please visit the
company's website at www.loxooncology.com.
Forward Looking Statements This press release
contains "forward-looking" statements within the meaning of the
safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. Forward-looking statements can be identified by
words such as: "anticipate," "intend," "plan," "goal," "seek,"
"believe," "project," "estimate," "expect," "strategy," "future,"
"likely," "may," "should," "will" and similar references to future
periods. These statements are subject to numerous risks and
uncertainties that could cause actual results to differ materially
from what we expect. Examples of forward-looking statements
include, among others, the reporting, timing and success of our
clinical trials or LOXO-292. Further information on potential risk
factors that could affect our business and its financial results
are detailed in our most recent Annual Report on Form 10-K, and
other reports as filed from time to time with the Securities
and Exchange Commission. We undertake no obligation to publicly
update any forward-looking statement, whether written or oral, that
may be made from time to time, whether as a result of new
information, future developments or otherwise.
Contacts for Loxo Oncology, Inc.
Company/Investors:Lauren CohenDirector, Corporate
Communicationslcohen@loxooncology.com
Media:Dan Budwick1AB Media973-271-6085dan@1abmedia.com
LOXO ONCOLOGY, INC. (NASDAQ:LOXO)
Historical Stock Chart
From Jun 2024 to Jul 2024
LOXO ONCOLOGY, INC. (NASDAQ:LOXO)
Historical Stock Chart
From Jul 2023 to Jul 2024